Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2013-01-24

Clinical Trial Update: A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers [Phase 1]

View source ↗

Summary

A Phase 1 study of AVI-7537 in healthy adult volunteers for Ebola virus disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AVI-7537

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Ebola Hemorrhagic Fever | Phase 1 | Status: WITHDRAWN